Academy Bio-Medical Company, Inc. specializes in Human Lipoproteins, Apolipoproteins, and Polyclonal Antibodies. Manufacturing and supplying high quality antibodies at affordable prices.
The company has been supporting the cardiovascular and atherosclerosis research community with research reagents since 1995. We are proud to offer our antibodies and reagents devoted to research in the area of lipoproteins, apolipoproteins, and their oxidatively modified products. Our antibody products are fully supported by our technical service experts.
Founder and CEO
Dr. Chao-Yuh Yang, one of the foremost experts in the area of human plasma lipoproteins and apolipoproteins, is the current Chief Executive Officer of Academy Bio-Medical Company. Previously, he was the Scientific and Technical Director of Academy Bio-Medical Company. Dr. Yang has over 40 years of experience in protein chemistry research, including 30 years of direct research experience in the field of lipoproteins and apolipoproteins. As a scientist in the Department of Immunochemistry, Max-Planck Institute for Experimental Medicine, Germany, he specialized in the structure of immunoglobulin IgA, IgG, and Histocompatibility Antigens HLA. For almost 3 decades, Dr. Yang was a member of the faculty at the Baylor College of Medicine in Houston, Texas, and he remains Professor Emeritus in Baylor’s Department of Medicine.
Dr. Yang's long-standing research interest has focused on the role of low density lipoproteins (LDLs) in atherosclerosis. His expertise is in the area of plasma oxidized LDL, structure-function relationships of human plasma lipoproteins and apolipoproteins, and their lipid-related enzymes. He played a key role in the determination of the complete Apo B-100 amino acid sequence (Yang et al., Nature 1986). Dr. Yang has authored over 100 peer-reviewed scientific articles in his field and has been invited to deliver presentations at numerous national and international conferences. He received his Ph.D. in organic chemistry from Georg-August University in Göttingen, Germany.
Schmatic represenation of apo B-100 structure on low density lipoprotein (LDL)
This is based on its trypsin releasability, disulfide, and sulhydryl information. The locations of the 16 identified N-glycosylated carbohydrates are indicated by (○), cysteine residues are indicated by (●), and disulfide bridges are indicated by (=). (Yang et al., Arteriosclerosis, Thrombosis, and Vascular Biology (1989), with permission)